[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Catheter-Related Bloodstream Infections (CRBSIs)- Epidemiology Forecast-2028

September 2019 | 100 pages | ID: CD34203F30EEN
DelveInsight

US$ 2,600.00 US$ 3,250.00 -20 %
Offer valid until December 31, 2019!

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
This report can be delivered to the clients within 24 hours

DelveInsight’s Catheter-Related Bloodstream Infections (CRBSIs)- Epidemiology Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology trends of CRBSI in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017–2028

Catheter-Related Bloodstream Infections (CRBSIs) - Disease Understanding

CRBSI refers to bloodstream infection attributed to an intravascular catheter by quantitative culture of the catheter tip or by differences in growth between catheter and peripheral venipuncture blood culture specimens. It is also known as catheter-related sepsis.

In the current scenario, there is no US Food and Drug Administration (FDA) approved drugs/lock solution present in the market, specifically for this indication, and therefore, the availability of new therapies will be the major market driver for the therapeutic market of CRBSI. Only one emerging therapy is present, which is in pipeline, i.e. Mino-Lok Therapy by Citius Pharmaceuticals. Due to non-competitiveness and poor pipeline, the launch of Mino-lok in the US or EU will create a huge hype and will have the only candidate in the CRBSI therapeutic landscape. The treatment of CRBSI is mainly preventive and is done by using off-label antibiotics. So, the need for a potential drug candidate is necessary and urgent.

Catheter-Related Bloodstream Infections (CRBSIs) – Epidemiology

The CRBSI epidemiology division provides insights about historical and current patient pool and forecasted trends for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders (KOL).

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Incident Population of CRBSI in the 7MM, Total Diagnosed Incident Population of CRBSI in the 7MM, and Diagnosed Incidence of CRBSI by Causative Pathogens in the 7MM] scenario of CRBSI in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017–2028.

As per DelveInsight’s analysis, total Incident Population of Catheter-Related Bloodstream Infection (CRBSI in the 7MM was found to be 667,753 in 2017 and expected to increase during the forecast period of 2017-2028. The estimates show the incidence was higher in the United States and among the European 5 countries, Germany had the highest incident population of CRBSI followed by France and United Kingdom. On the other hand, Spain had the lowest incident population of CRBSI.

Another estimate of Delveinsight’s analysis shows that most of the incident cases of CRBSI are confirmed with specific bacterial species. The estimates show that Gram-positive bacteria are implicated in the majority of the cases of CRBSI in comparison with Gram-negative bacteria.

REPORT SCOPE
  • The report covers detailed overview of Catheter-related Bloodstream Infections explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the UK) & Japan
  • The Report assesses the disease risk and burden and highlights the unmet needs of Catheter-related Bloodstream Infections
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by type specific cases and severity specific cases of Catheter-related Bloodstream Infections in the 7MM
Catheter-related Bloodstream Infections Report Key Strengths
  • 10 Year Forecast of Catheter-related Bloodstream Infections epidemiology
  • 7MM Coverage
  • Total Incident Population of CRBSI
  • Total Diagnosed Incident Population of CRBSI
  • Diagnosed Incidence of CRBSI by Causative Pathogens
Catheter-related Bloodstream Infections Report Assessment
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
1. KEY INSIGHTS

2. CATHETER-RELATED BLOOD STREAM INFECTION (CRBSI) EPIDEMIOLOGY OVERVIEW AT A GLANCE

2.1. Total Epidemiology Distribution of CRBSI in 2017
2.2. Total Epidemiology Distribution of CRBSI in 2028

3. CATHETER-RELATED BLOODSTREAM INFECTION (CRBSI): DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Difference between CLABSI and CRBSI
3.3. Causes of Catheter-Related Bloodstream Infection (CRBSI)
  3.3.1. Micro-organisms
  3.3.2. Intravascular Devices
3.4. Risk Factor Associated with Catheter-Related Bloodstream Infection (CRBSI)
3.5. Pathogenesis of Catheter-Related Bloodstream Infection (CRBSI)
3.6. Diagnosis of Catheter-Related Bloodstream Infection (CRBSI)
3.7. Diagnosis Guidelines Catheter-Related Bloodstream Infection (CRBSI)
  3.7.1. Infectious Diseases Society of America (IDSA) Guidelines for CRBSI
  3.7.2. Spanish Society of Infectious Diseases and Clinical Microbiology and (SEIMC) and the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC)
  3.7.3. British Intestinal Failure Alliance (BIFA):
  3.7.4. European Renal Best Practice (ERBP) Recommendations for Diagnosis of CRBSIs

4. EPIDEMIOLOGY AND PATIENT POPULATION

4.1. Key Findings
4.2. Total Incident Population of CRBSI in the 7MM
4.3. Total Diagnosed Incident Population of CRBSI in the 7MM
4.4. Diagnosed Incidence of CRBSI by Causative Pathogens in the 7MM
4.5. Some KOL Insights

5. UNITED STATES EPIDEMIOLOGY

5.1. Assumptions and Rationale
5.2. Total Incident Population of CRBSI in the United States
5.3. Total Diagnosed Incident Population of CRBSI in the United States
5.4. Diagnosed Incidence of CRBSI by Causative Pathogens in the United States

6. EU5 EPIDEMIOLOGY

6.1. Germany Epidemiology
  6.1.1. Assumptions and Rationale
  6.1.2. Total Incident Population of CRBSI in Germany
  6.1.3. Total Diagnosed Incident Population of CRBSI in Germany
  6.1.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Germany
6.2. France Epidemiology
  6.2.1. Assumptions and rationale
  6.2.2. Total Incident Population of CRBSI in France
  6.2.3. Total Diagnosed Incident Population of CRBSI in France
  6.2.4. Diagnosed Incidence of CRBSI by Causative Pathogens in France
6.3. Italy Epidemiology
  6.3.1. Assumptions and Rationale
  6.3.2. Total Incident Population of CRBSI in Italy
  6.3.3. Total Diagnosed Incident Population of CRBSI in Italy
  6.3.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Italy
6.4. Spain Epidemiology
  6.4.1. Assumptions and Rationale
  6.4.2. Total Incident Population of CRBSI in Spain
  6.4.3. Total Diagnosed Incident Population of CRBSI in Spain
  6.4.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Spain
6.5. United Kingdom Epidemiology
  6.5.1. Assumptions and Rationale
  6.5.2. Total Incident Population of CRBSI in the United Kingdom
  6.5.3. Total Diagnosed Incident Population of CRBSI in the United Kingdom
  6.5.4. Diagnosed Incidence of CRBSI by Causative Pathogens in the United Kingdom

7. JAPAN EPIDEMIOLOGY

7.1. Assumptions and Rationale
7.2. Total Incident Population of CRBSI in Japan
7.3. Total Diagnosed Incident Population of CRBSI in Japan
7.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Japan

8. APPENDIX

8.1. Report Methodology

9. DELVEINSIGHT CAPABILITIES

10. DISCLAIMER

11. ABOUT DELVEINSIGHT

LIST OF TABLES

TABLE 1: TERMINOLOGY: CLABSI OR CRBSI
TABLE 2: VARIOUS RISK FACTORS OF CRBSI
TABLE 3: TOTAL INCIDENT POPULATION OF CRBSI IN THE 7MM (2017–2028)
TABLE 4: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN THE 7MM (2017–2028)
TABLE 5: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN THE 7MM (2017–2028)
TABLE 6: TOTAL INCIDENT POPULATION OF CRBSI IN THE US (2017–2028)
TABLE 7: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN THE US (2017–2028)
TABLE 8: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN THE US (2017–2028)
TABLE 9: TOTAL INCIDENT POPULATION OF CRBSI IN GERMANY (2017–2028)
TABLE 10: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN GERMANY (2017–2028)
TABLE 11: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN GERMANY (2017–2028)
TABLE 12: TOTAL INCIDENT POPULATION OF CRBSI IN FRANCE (2017–2028)
TABLE 13: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN FRANCE (2017–2028)
TABLE 14: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN FRANCE (2017–2028)
TABLE 15: TOTAL INCIDENT POPULATION OF CRBSI IN ITALY (2017–2028)
TABLE 16: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN ITALY (2017–2028)
TABLE 17: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN ITALY (2017–2028)
TABLE 18: TOTAL INCIDENT POPULATION OF CRBSI IN SPAIN (2017–2028)
TABLE 19: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN SPAIN (2017–2028)
TABLE 20: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN SPAIN (2017–2028)
TABLE 21: TOTAL INCIDENT POPULATION OF CRBSI IN THE UK (2017–2028)
TABLE 22: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN THE UK (2017–2028)
TABLE 23: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN THE UK (2017–2028)
TABLE 24: TOTAL INCIDENT POPULATION OF CRBSI IN THE JAPAN (2017–2028)
TABLE 25: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN THE JAPAN (2017–2028)
TABLE 26: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN JAPAN (2017–2028)

LIST OF FIGURES

Figure 1: Types of Central Venous and Arterial Catheter and their sites of insertion
Figure 2: Important pathogenic determinants of catheter-related infections
Figure 3: Potential sources of infection of a percutaneous intravascular device
Figure 4: Total Incident Population of CRBSI in the 7MM (2017–2028)
Figure 5: Total Diagnosed Incident Population of CRBSI in the 7MM (2017–2028)
Figure 6: Diagnosed Incidence of CRBSI by Causative Pathogens in the 7MM (2017–2028)
Figure 7: Total Incident Population of CRBSI in the US (2017–2028)
Figure 8: Total Diagnosed Incident Population of CRBSI in the US (2017–2028)
Figure 9: Diagnosed Incidence of CRBSI by Causative Pathogens in the US (2017–2028)
Figure 10: Total Incident Population of CRBSI in Germany (2017–2028)
Figure 11: Total Diagnosed Incident Population of CRBSI in Germany (2017–2028)
Figure 12: Diagnosed Incidence of CRBSI by Causative Pathogens in Germany (2017–2028)
Figure 13: Total Incident Population of CRBSI in France (2017–2028)
Figure 14: Total Diagnosed Incident Population of CRBSI in France (2017–2028)
Figure 15: Diagnosed Incidence of CRBSI by Causative Pathogens in France (2017–2028)
Figure 16: Total Incident Population of CRBSI in Italy (2017–2028)
Figure 17: Total Diagnosed Incident Population of CRBSI in Italy (2017–2028)
Figure 18: Diagnosed Incidence of CRBSI by Causative Pathogens in Italy (2017–2028)
Figure 19: Total Incident Population of CRBSI in Spain (2017–2028)
Figure 20: Total Diagnosed Incident Population of CRBSI in Spain (2017–2028)
Figure 21: Diagnosed Incidence of CRBSI by Causative Pathogens in Spain (2017–2028)
Figure 22: Total Incident Population of CRBSI in the United Kingdom (2017–2028)
Figure 23: Total Diagnosed Incident Population of CRBSI in the United Kingdom (2017–2028)
Figure 24: Diagnosed Incidence of CRBSI by Causative Pathogens in the United Kingdom (2017–2028)
Figure 25: Total Incident Population of CRBSI in Japan (2017–2028)
Figure 26: Total Diagnosed Incident Population of CRBSI in Japan (2017–2028)
Figure 27: Diagnosed Incidence of CRBSI by Causative Pathogens in Japan (2017–2028)


More Publications